S&P 500

5.460,48

-0,41%

Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.

Cadastre-se

Início
Investir
Ações
Canadá
TSX
Eupraxia Pharmaceuticals Inc (EPRX)
Eupraxia Pharmaceuticals Inc (EPRX) Notícias

EPRX

Eupraxia Pharmaceuticals (EPRX)

Eupraxia Pharmaceuticals Inc

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:TSX:EPRX

1 2 3 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
06/06/2024	18:00	PR Newswire (US)	Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders	TSX:EPRX	Eupraxia Pharmaceuticals Inc
05/06/2024	08:00	PR Newswire (US)	Eupraxia Pharmaceuticals to Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024	TSX:EPRX	Eupraxia Pharmaceuticals Inc
23/05/2024	18:00	PR Newswire (Canada)	Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis	TSX:EPRX	Eupraxia Pharmaceuticals Inc
22/05/2024	08:00	PR Newswire (US)	Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024	TSX:EPRX	Eupraxia Pharmaceuticals Inc
21/05/2024	18:00	PR Newswire (Canada)	Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis	TSX:EPRX	Eupraxia Pharmaceuticals Inc
14/05/2024	08:00	PR Newswire (US)	Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024	TSX:EPRX	Eupraxia Pharmaceuticals Inc
08/05/2024	18:03	PR Newswire (US)	Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update	TSX:EPRX	Eupraxia Pharmaceuticals Inc
02/05/2024	08:00	PR Newswire (US)	Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board	TSX:EPRX	Eupraxia Pharmaceuticals Inc
11/04/2024	08:00	PR Newswire (US)	Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024	TSX:EPRX	Eupraxia Pharmaceuticals Inc
08/04/2024	08:00	PR Newswire (US)	Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor Conference	TSX:EPRX	Eupraxia Pharmaceuticals Inc
05/04/2024	08:00	PR Newswire (US)	Eupraxia Pharmaceuticals Begins Trading on Nasdaq Today	TSX:EPRX	Eupraxia Pharmaceuticals Inc
03/04/2024	18:00	PR Newswire (Canada)	Eupraxia Pharmaceuticals to Begin Trading on Nasdaq on April 5, 2024	TSX:EPRX	Eupraxia Pharmaceuticals Inc
01/04/2024	18:01	PR Newswire (Canada)	Eupraxia Pharmaceuticals Reports Fourth Quarter and 2023 Financial Results	TSX:EPRX	Eupraxia Pharmaceuticals Inc
12/03/2024	10:41	PR Newswire (Canada)	L'Organisme canadien de réglementation des investissements permet la reprise de la négociation - EPRX	TSX:EPRX	Eupraxia Pharmaceuticals Inc
12/03/2024	10:39	PR Newswire (Canada)	Canadian Investment Regulatory Organization Trade Resumption - EPRX	TSX:EPRX	Eupraxia Pharmaceuticals Inc
11/03/2024	17:06	PR Newswire (Canada)	Suspension de la négociation par l'Organisme canadien de réglementation des investissements - EPRX	TSX:EPRX	Eupraxia Pharmaceuticals Inc
11/03/2024	17:04	PR Newswire (Canada)	Canadian Investment Regulatory Organization Trading Halt - EPRX	TSX:EPRX	Eupraxia Pharmaceuticals Inc
05/02/2024	19:00	PR Newswire (Canada)	Eupraxia Pharmaceuticals Announces Updated Positive Clinical Data in EP-104GI RESOLVE Trial for the Treatment of Eosinophilic Esophagitis	TSX:EPRX	Eupraxia Pharmaceuticals Inc
01/02/2024	09:00	PR Newswire (Canada)	Eupraxia Pharmaceuticals Initiates Phase 3 Development Program for EP-104IAR	TSX:EPRX	Eupraxia Pharmaceuticals Inc
30/01/2024	09:00	PR Newswire (Canada)	Eupraxia Pharmaceuticals Announces Positive Data from MRI Exploratory Sub-Study in Phase 2 SPRINGBOARD Trial Evaluating the Safety and Efficacy of EP-104IAR for the Treatment of Osteoarthritis of the Knee	TSX:EPRX	Eupraxia Pharmaceuticals Inc
08/01/2024	20:44	PR Newswire (Canada)	Eupraxia Pharmaceuticals Announces Filing of Preliminary MJDS Base Shelf Prospectus	TSX:EPRX	Eupraxia Pharmaceuticals Inc
12/12/2023	09:00	PR Newswire (Canada)	Eupraxia Pharmaceuticals Announces Positive Clinical Data in EP-104GI RESOLVE Trial	TSX:EPRX	Eupraxia Pharmaceuticals Inc
11/12/2023	09:00	PR Newswire (Canada)	Eupraxia Pharmaceuticals Announces Clinical and Corporate Update	TSX:EPRX	Eupraxia Pharmaceuticals Inc
14/11/2023	19:01	PR Newswire (Canada)	Eupraxia Pharmaceuticals Reports Third Quarter 2023 Financial Results	TSX:EPRX	Eupraxia Pharmaceuticals Inc
01/11/2023	08:00	PR Newswire (Canada)	Eupraxia Pharmaceuticals to Present at the 2023 Annual Meeting of the American College of Rheumatology	TSX:EPRX	Eupraxia Pharmaceuticals Inc
11/10/2023	08:00	PR Newswire (Canada)	Eupraxia Pharmaceuticals Announces Initiation of Second Cohort in Phase 1b/2a Clinical Trial in Eosinophilic Esophagitis	TSX:EPRX	Eupraxia Pharmaceuticals Inc
11/09/2023	16:32	PR Newswire (Canada)	Eupraxia Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference	TSX:EPRX	Eupraxia Pharmaceuticals Inc
07/09/2023	18:00	PR Newswire (Canada)	Eupraxia Pharmaceuticals Announces Change of Auditor	TSX:EPRX	Eupraxia Pharmaceuticals Inc
06/09/2023	18:00	PR Newswire (Canada)	Eupraxia Pharmaceuticals Announces Presentation at PAINWeek 2023	TSX:EPRX	Eupraxia Pharmaceuticals Inc
18/08/2023	20:20	PR Newswire (Canada)	Eupraxia Pharmaceuticals Announces Closing of Non-Brokered Private Placement for Gross Proceeds of C$22,287,125	TSX:EPRX	Eupraxia Pharmaceuticals Inc